<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1216</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>14978120</PubmedId>
            <Abstract>Viral infections have been shown to induce lymphopenias that lower memory CD8 T cell frequencies, and they also have been shown to cause a permanent loss of memory cells specific to previously encountered pathogens. In this study, the patterns and significance of virus-induced memory CD8 T cell depletion were examined in mice immune to heterologous (Pichinde, vesicular stomatitis, vaccinia) viruses and subsequently challenged with acute or persistent lymphocytic choriomeningitis virus infections. Memory CD8 T cell loss was comprehensive and occurred in both lymphoid and peripheral tissues of the immune host. The impact of the loss of memory T cells was reflected by in vivo cytotoxicity assays, which showed decreased clearance of epitope-expressing targets. Memory CD8 T cell loss occurred very early (day 2) after infection, and was thereafter sustained, consistent more with an active deletion model than with a competition model. Cross-reactive T cells, in contrast, increased in number, but memory cells were reduced whether or not there was competition from cross-reactive T cells. Memory T cell loss was more profound during persistent infection than after acute infection. Adoptive transfer studies showed that, unlike the resolved acute infection, in which the reduced memory frequencies became stable, memory T cell loss was a continuously ongoing process during persistent infection. This study therefore links an early virus-induced lymphopenia to a subsequent long-term loss of CD8 T cell memory and offers a new mechanism for immune deficiency during persistent viral infections.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>3139-50</ArticlePages>
            <ArticleTitle>Comprehensive early and lasting loss of memory CD8 T cells and functional memory during acute and persistent viral infections.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Sung-Kwon</ForeName>
                </Author>
                <Author>
                    <LastName>Welsh</LastName>
                    <ForeName>Raymond M</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Pathology, University of Massachusetts Medical Center, Worcester, MA 01655, USA.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;Nuclear Proteins;Viral Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Acute Disease; Animals; CD8-Positive T-Lymphocytes(immunology; pathology; virology); Cell Survival(immunology); Chronic Disease; Cytotoxicity, Immunologic; Epitopes, T-Lymphocyte(immunology); Immunologic Memory; Kinetics; Lymphocyte Count; Lymphocytic Choriomeningitis(immunology; pathology; virology); Lymphopenia(immunology; pathology; virology); Male; Mice; Mice, Inbred C57BL; Nuclear Proteins(chemistry; immunology); Peritoneum(immunology; virology); Pichinde virus(immunology); T-Lymphocyte Subsets(immunology; pathology; virology); Time Factors; Vaccinia virus(immunology); Vesicular stomatitis Indiana virus(immunology); Viral Proteins(chemistry; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>172</Volume>
                <Issue>5</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP 38-45</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SALDFHKV</LinearSequence>
                        <StartingPosition>38</StartingPosition>
                        <EndingPosition>45</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03541.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>2169993</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3140</LocationOfData>
                <EpitopeId>56850</EpitopeId>
                <ReferenceStartingPosition>38</ReferenceStartingPosition>
                <ReferenceEndingPosition>45</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>17827</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>M</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>2169993</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of PV (2x10&lt;sup&gt;7&lt;/sup&gt; PFU) was followed by a dose of LCMV 6 weeks after (Armstrong strain: 5x10&lt;sup&gt;4&lt;/sup&gt; PFU, Clone 13 strain: 5x10&lt;sup&gt;6&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Either Armstrong (acute infection ) or Clone 13 (persistent infection) strains of LCMV where used for secondary infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 38-45</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SALDFHKV</LinearSequence>
                                        <StartingPosition>38</StartingPosition>
                                        <EndingPosition>45</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03541.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>2169993</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Functional memory CD8+ epitope specific cells are reduced after resolution of a subsequent acute LCMV (Armstrong strain) secondary infection or when the secondary infection is with a persistent LCMV (Clone 13) virus. The number and not only the functionality is compromised by the secondary LCMV infection. Similar reductions are seen in the peritoneum and lungs. This attrition peaks at day 9 post secondary infection. When persistent infection by clone 13 LCMV is induced, no recovery of the memory T cell population is seen up to 40 days later, while a partial recovery is seen in acute Armstrong LCMV secondary infection. The process or heterologous memory T cell loss  is related to the LCMV induced  lymphopenia which preferentially reduces the CD44high CD8+ phenotype, and  is evident 2 days after secondary infection. Adoptive transfer experiments at day 42 after infection with Clone 13 LCMV showed that the deletion of these cells is an active process, operational as long as infection with LCMV persists.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>17828</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>M</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>2169993</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of PV (2x10&lt;sup&gt;7&lt;/sup&gt; PFU) was followed by a dose of LCMV 6 weeks after (Armstrong strain: 5x10&lt;sup&gt;4&lt;/sup&gt; PFU, Clone 13 strain: 5x10&lt;sup&gt;6&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Either Armstrong (acute infection ) or Clone 13 (persistent infection) strains of LCMV where used for secondary infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>In Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 38-45</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SALDFHKV</LinearSequence>
                                        <StartingPosition>38</StartingPosition>
                                        <EndingPosition>45</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03541.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>2169993</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>246</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>In vivo cytotoxicity against peptide pulsed APCs is highly efficient (90% of cells killed in 24h) in source species immune mice, but reduced to 28% with subsequent acute LCMV (Armstrong strain) secondary infection, and to 21% when the secondary infection is with a persistent LCMV (Clone 13) virus. The process or heterologous memory T cell loss with reduced cytotoxic activity  is related to the LCMV induced lymphopenia which preferentially reduces the CD44high CD8+ phenotype and  is evident 2 days after secondary infection, and seen in both spleen and lungs.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP 122-132</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VYEGNLTNTQL</LinearSequence>
                        <StartingPosition>122</StartingPosition>
                        <EndingPosition>132</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03541.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>2169993</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3140</LocationOfData>
                <EpitopeId>72011</EpitopeId>
                <ReferenceStartingPosition>122</ReferenceStartingPosition>
                <ReferenceEndingPosition>132</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>17829</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>M</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>2169993</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of PV (2x10&lt;sup&gt;7&lt;/sup&gt; PFU) was followed by a dose of LCMV 6 weeks after (Armstrong strain: 5x10&lt;sup&gt;4&lt;/sup&gt; PFU, Clone 13 strain: 5x10&lt;sup&gt;6&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Either Armstrong (acute infection ) or Clone 13 (persistent infection) strains of LCMV where used for secondary infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 122-132</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VYEGNLTNTQL</LinearSequence>
                                        <StartingPosition>122</StartingPosition>
                                        <EndingPosition>132</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03541.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>2169993</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Functional memory CD8+ epitope specific cells in spleens of source species immune mice are reduced from 3.2% to 1% after resolution of a subsequent acute LCMV (Armstrong strain) secondary infection, and to 0.3% when the secondary infection is with a persistent LCMV (Clone 13) virus. This effect is also seen in the peritoneum and lungs. The process or heterologous memory T cell loss  is related to the LCMV induced lymphopenia which preferentially reduces the CD44high CD8+ phenotype and is evident 2 days after secondary infection and is mediated by the deletion of these cells as an active process, operational as long as infection with LCMV persists.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP 205-212</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YTVKFPNM</LinearSequence>
                        <StartingPosition>205</StartingPosition>
                        <EndingPosition>212</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03541.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>2169993</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3140</LocationOfData>
                <EpitopeId>76204</EpitopeId>
                <ReferenceStartingPosition>205</ReferenceStartingPosition>
                <ReferenceEndingPosition>212</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Weak subdominant epitope in anti-PV response, that share 6 of 8 resiudes with NP 205-212 from LCMV nucleoprotein.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>17831</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>M</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>2169993</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of PV (2x10&lt;sup&gt;7&lt;/sup&gt; PFU) was followed by a dose of LCMV 6 weeks after (Armstrong strain: 5x10&lt;sup&gt;4&lt;/sup&gt; PFU, Clone 13 strain: 5x10&lt;sup&gt;6&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Either Armstrong (acute infection ) or Clone 13 (persistent infection) strains of LCMV where used for secondary infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 205-212</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YTVKFPNM</LinearSequence>
                                        <StartingPosition>205</StartingPosition>
                                        <EndingPosition>212</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03541.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>2169993</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Functional memory CD8+ epitope specific cells in spleens of source species immune mice are low, as a subdominant epitope, and expanded after resolution of a subsequent acute LCMV (Armstrong strain) secondary infection, that carry a cross-reactive epitope. When the secondary infection is with a persistent LCMV (Clone 13) virus, no enhancement is seen, as this strain is known to delete or anergize the T cells directed against its epitopes. This pattern is also reflected by tetramer staining, indicating the number and not only the functionality is affected by the secondary LCMV infection. This effect is also seen in the peritoneum and lungs. The kinetics of this change includes an early T cell expansion after secondary infection with either strain, that is maintained in Armstrong infected animals, but subsequently down regulated in Clone 13 infected mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>17832</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>M</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>2169993</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of PV (2x10&lt;sup&gt;7&lt;/sup&gt; PFU) was followed by a dose of LCMV 6 weeks after (Armstrong strain: 5x10&lt;sup&gt;4&lt;/sup&gt; PFU, Clone 13 strain: 5x10&lt;sup&gt;6&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Either Armstrong (acute infection ) or Clone 13 (persistent infection) strains of LCMV where used for secondary infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>In Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 205-212</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YTVKFPNM</LinearSequence>
                                        <StartingPosition>205</StartingPosition>
                                        <EndingPosition>212</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03541.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>2169993</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>246</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>In vivo cytotoxicity against peptide pulsed APCs is low (3% of cells killed in 24h), as a subdominant epitope, and expanded to 54% after resolution of a subsequent acute LCMV (Armstrong strain) secondary infection, that carry a cross-reactive epitope. When the secondary infection is with a persistent LCMV (Clone 13) virus, less enhancement  (16%) is seen, as this strain is known to delete or anergize the T cells directed against its epitopes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP 33-41</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KAVYNFATC</LinearSequence>
                        <StartingPosition>33</StartingPosition>
                        <EndingPosition>41</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11623</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3140</LocationOfData>
                <EpitopeId>30001</EpitopeId>
                <ReferenceStartingPosition>33</ReferenceStartingPosition>
                <ReferenceEndingPosition>41</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>17833</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>M</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of PV (2x10&lt;sup&gt;7&lt;/sup&gt; PFU) was followed by a dose of LCMV 6 weeks after (Armstrong strain: 5x10&lt;sup&gt;4&lt;/sup&gt; PFU, Clone 13 strain: 5x10&lt;sup&gt;6&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Either Armstrong (acute infection ) or Clone 13 (persistent infection) strains of LCMV where used for secondary infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP 33-41</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAVYNFATC</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>41</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Memory CD8+ epitope specific cells are seen in spleens of Pichide Virus immune mice secondarily infected with source species Armstrong strain (with 1.34% of epitope specific CD44+ cells 6 wk after secondary infection) and when the secondary infection is with the persistent LCMV Clone 13 virus (with 0.8%), even whith a profound attrition in the memory response to the PV epitope, implying that attrition is a phenomena requiring deletion and not apparent because of dilution due to expansion of LCMV specific cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP 276-286</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SGVENPGGYCL</LinearSequence>
                        <StartingPosition>276</StartingPosition>
                        <EndingPosition>286</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11623</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3140</LocationOfData>
                <EpitopeId>58282</EpitopeId>
                <ReferenceStartingPosition>276</ReferenceStartingPosition>
                <ReferenceEndingPosition>286</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>17835</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>M</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of PV (2x10&lt;sup&gt;7&lt;/sup&gt; PFU) was followed by a dose of LCMV 6 weeks after (Armstrong strain: 5x10&lt;sup&gt;4&lt;/sup&gt; PFU, Clone 13 strain: 5x10&lt;sup&gt;6&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Either Armstrong (acute infection ) or Clone 13 (persistent infection) strains of LCMV where used for secondary infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP 276-286</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGVENPGGYCL</LinearSequence>
                                        <StartingPosition>276</StartingPosition>
                                        <EndingPosition>286</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Memory CD8+ epitope specific cells are seen in simliar levels in spleens of Pichide Virus (PV) immune mice secondarily infected with source species Armstrong strain (acute infeection) or with the persistent Clone 13 virus (1.7-1.8% 6 wk after secondary infection), even with a profound attrition in the memory response to the PV epitope, implying that attrition is a phenomena requiring deletion and is not apparent because of dilution due to expansion of LCMV specific cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP 51-59</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RGYVYQGL</LinearSequence>
                        <StartingPosition>52</StartingPosition>
                        <EndingPosition>59</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAM84178.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11276</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3140</LocationOfData>
                <EpitopeId>54039</EpitopeId>
                <ReferenceStartingPosition>52</ReferenceStartingPosition>
                <ReferenceEndingPosition>59</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>17836</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>M</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11276</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of VSV (1x10^6 PFU) was followed by a dose of LCMV 6 weeks after (Armstrong strain: 5x10&lt;sup&gt;4&lt;/sup&gt; PFU, Clone 13 strain: 5x10&lt;sup&gt;6&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Either Armstrong (acute infection ) or Clone 13 (persistent infection) strains of LCMV where used for secondary infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 51-59</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RGYVYQGL</LinearSequence>
                                        <StartingPosition>52</StartingPosition>
                                        <EndingPosition>59</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAM84178.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11276</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Functional memory CD8+ epitope specific cells in spleens of source species immune mice are reduced from 2.4% to 0.7% after resolution of a subsequent acute LCMV (Armstrong strain) secondary infection, and to 0.2% when the secondary infection is with a persistent LCMV (Clone 13) virus. The process or heterologous memory T cell loss  is related to the LCMV induced  lymphopenia which preferentially reduces the CD44high CD8+ phenotype and  is evident 2 days after secondary infection and mediated by the deletion of these cells as an active process, operational as long as infection with LCMV persists.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>17837</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>M</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11276</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of VSV (1x10^6 PFU) was followed by a dose of LCMV 6 weeks after (Armstrong strain: 5x10&lt;sup&gt;4&lt;/sup&gt; PFU, Clone 13 strain: 5x10&lt;sup&gt;6&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Either Armstrong (acute infection ) or Clone 13 (persistent infection) strains of LCMV where used for secondary infection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>In Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 51-59</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RGYVYQGL</LinearSequence>
                                        <StartingPosition>52</StartingPosition>
                                        <EndingPosition>59</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAM84178.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11276</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>246</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>In vivo cytotoxicity against peptide pulsed APCs is shown to be highly efficient (90% of cells killed in 24h) in source species immune mice, but to be reduced to 70% when mice had a subsequent acute LCMV (Armstrong strain) secondary infection, and to 15% when the secondary infection is with a persistent LCMV (Clone 13) virus.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

